Viral Hepatitis — GCC Nursing Guide

Hepatitis A & E — Enterically Transmitted Hepatitis

Hepatitis A (HAV)

Key Facts

Route: Faecal-oral (contaminated food/water, shellfish, person-to-person)
Incubation: 15–50 days (avg 28 days)
Chronicity: Never becomes chronic
Immunity: Lifelong after infection
Mortality: <0.1% (higher in elderly, chronic liver disease)
Infectivity peak: 2 weeks before — 1 week after jaundice

Clinical Features

Prodrome: fever, fatigue, nausea, anorexia, RUQ pain
Icteric phase: jaundice, dark urine, pale stools, pruritus
Children often asymptomatic; adults more symptomatic

Diagnosis

Anti-HAV IgM — acute infection (positive from symptom onset, lasts ~3 months)
Anti-HAV IgG — past infection or vaccination
Elevated ALT/AST (can be >1000 IU/L)

Hepatitis E (HEV)

Key Facts

Route: Waterborne (genotype 1,2); Zoonotic — undercooked pork/wild boar (genotype 3,4)
Incubation: 15–60 days
Chronicity: No chronic phase in immunocompetent (except genotype 3 in immunocompromised)
Genotypes 1&2: Developing countries, epidemic form, waterborne
Genotypes 3&4: Developed countries/zoonotic, sporadic

⚠

High Mortality in Pregnancy: HEV genotype 1 causes fulminant hepatic failure in 15–25% of pregnant women (3rd trimester). Maternal mortality up to 25%. Fetal/neonatal mortality also elevated. Screen all jaundiced pregnant patients.

Diagnosis

Anti-HEV IgM (acute) / IgG (past)
HEV RNA (PCR) — most sensitive, especially immunocompromised
No licensed vaccine widely available outside China (HEV 239)

HAV Vaccination & Post-Exposure Prophylaxis

Vaccination Schedule

2-dose schedule: 0 and 6–12 months
Combined HAV/HBV (Twinrix): 0, 1, 6 months
Efficacy: >94% seroprotection after 2 doses
Duration: >25 years (likely lifelong)

Indications for Vaccination

Travellers to endemic regions
MSM, PWID, homeless individuals
Chronic liver disease (high risk of fulminant HAV)
Healthcare workers in high-risk settings
Food handlers (GCC requirement)

Post-Exposure Prophylaxis (within 2 weeks)

<40 years, healthy: HAV vaccine preferred
>40 years, immunocompromised, chronic liver disease: Immunoglobulin (0.1 mL/kg IM) ± vaccine
Infants <12 months: Immunoglobulin only

Acute Hepatitis Management

Supportive Care

Rest: Activity as tolerated; bed rest not mandatory
Nutrition: High-carbohydrate, low-fat diet; small frequent meals; IV fluids if vomiting
Avoid hepatotoxins: Alcohol (absolute), paracetamol (caution/avoid), NSAIDs, statins, herbal remedies
Medications review: Discontinue non-essential hepatically metabolised drugs

Nursing Monitoring

Daily LFTs (ALT, AST, bilirubin, ALP)
PT/INR — best marker of synthetic function
Blood glucose (risk of hypoglycaemia)
Fluid balance; daily weights
Mental status (early hepatic encephalopathy)

⚠ Fulminant Hepatic Failure (FHF) — Warning Signs

Clinical Red Flags

INR >1.5 (early), INR >2.0 (serious)
Encephalopathy (any grade)
Hypoglycaemia
Rapidly rising bilirubin
Falling ALT with rising bilirubin (hepatocyte loss)

Hepatic Encephalopathy Grades

Grade 1: Subtle confusion, sleep disturbance
Grade 2: Drowsiness, asterixis (flapping tremor)
Grade 3: Marked confusion, stupor
Grade 4: Coma

Immediate Actions

Contact senior/ICU team immediately
Consider urgent liver transplant assessment
IV dextrose for hypoglycaemia
Lactulose for encephalopathy
Avoid sedatives, opioids
Vitamin K for coagulopathy

Infection Control Measures

Standard Precautions (all hepatitis)

Hand hygiene — soap and water (preferred over ABHR for HAV/HEV due to non-enveloped virus)
PPE: gloves for all contact with body fluids
Safe sharps disposal
Environmental cleaning with approved disinfectants
Safe handling of patient linen

Contact Precautions (HAV/HEV specific)

Private room preferred for HAV inpatients (7 days after jaundice onset)
Gloves + apron for patient contact
Dedicated toilet facilities
Strict hand hygiene after toilet/before food
Exclude food handlers/healthcare staff until non-infectious
Notify public health for HAV (notifiable disease in GCC countries)

Hepatitis B — Serology, Natural History & Prevention

🧪 Interactive HBV Serology Interpreter

Select all markers that are positive in this patient, then click Interpret.

Select markers above and click Interpret...

Scenario	HBsAg	Anti-HBs	HBeAg	Anti-HBe	Anti-HBc IgM	Anti-HBc IgG	HBV DNA
Acute HBV	+	−	+	−	+	−/+	High
Window Period (early recovery)	−	−	−	±	+	+	Low/−
Resolved / Past Infection	−	+	−	±	−	+	−
Vaccinated	−	+	−	−	−	−	−
Chronic Active (HBeAg+)	+	−	+	−	−	+	High >10⁵
Chronic Active (HBeAg−)	+	−	−	+	−	+	Mod >10³
Inactive Carrier	+	−	−	+	−	+	<2000
Immune Tolerant	+	−	+	−	−	+	Very High
Functional Cure (HBsAg loss)	−	±	−	±	−	+	−

Key: Anti-HBc IgG alone (+) with HBsAg (−) and Anti-HBs (−) = occult HBV or resolved infection. Consider HBV DNA testing before immunosuppression.

Phases of Chronic HBV Infection

Immune Tolerant

Immune Active (HBeAg+)

Immune Active (HBeAg−)

Inactive Carrier

Reactivation

Phase	HBsAg	HBeAg	HBV DNA	ALT	Liver Inflammation	Treatment?
Immune Tolerant	+	+	Very High	Normal	Minimal	Usually No
Immune Active HBeAg+	+	+	High	Elevated	Active	Yes
Immune Active HBeAg−	+	−	Moderate	Elevated	Active	Yes
Inactive Carrier	+	−	Low/−	Normal	Minimal	No (monitor)
Reactivation	+	±	Rising	Rising	Active	Yes

Natural History & Complications

Perinatal infection: 90% chronic if untreated; highest risk
Childhood (1–5 yrs): 25–50% risk of chronic HBV
Adult acute HBV: Only 5% become chronic
Cirrhosis risk: 15–40% of untreated chronic HBV over 20 years
HCC risk: 2–5%/year in cirrhotics; even higher with HBeAg+, high HBV DNA, family history
Decompensated cirrhosis: 5-year survival <35% without transplant

⚠

HBV is the leading cause of HCC globally. HCC can arise even without cirrhosis in HBV patients.

HBV Vaccination Program

Standard Schedule (3-dose)

0 months: 1st dose (at birth or enrolment)
1 month: 2nd dose
6 months: 3rd dose

Accelerated (rapid immunity needed)

0, 7, 21 days then booster at 12 months

Response Assessment

Check anti-HBs 1–2 months after 3rd dose
Anti-HBs ≥10 mIU/mL: Seroprotected
Anti-HBs <10: Repeat series (up to 3 more doses)
Non-responders: Consider HBsAg test (may be chronically infected); advise ongoing precautions
Boosters not routinely needed in immunocompetent responders

GCC Requirement

Mandatory pre-employment HBV screen + vaccination for all healthcare workers in UAE, KSA, Qatar, Kuwait, Bahrain, Oman

Vertical Transmission Prevention & Healthcare Worker Exposure

Perinatal Transmission Prevention

Screen all pregnant women for HBsAg at booking visit

If HBsAg+: check HBV DNA. If >200,000 IU/mL → start tenofovir at 28 weeks (reduces transmission)

At birth (within 12 hours): HBV vaccine + HBIG 0.5mL IM (different sites)

Complete 3-dose vaccine series (0, 1, 6 months); check anti-HBs & HBsAg at 9 months

Breastfeeding is safe if infant received HBIG + vaccine

Healthcare Worker Needlestick / Exposure Protocol

Immediate: Wash wound thoroughly with soap and water; do not suck wound. Flush mucous membranes with water.

Report to occupational health / supervisor within 1–2 hours. Document time, device, source patient details.

Source patient testing: HBsAg, anti-HIV, HCV Ab (with consent)

If source HBsAg+ and exposed HCW unvaccinated/non-immune: HBIG within 24–48 hrs + commence vaccine series

Follow up HBsAg + anti-HBs at 6 weeks, 3 months, 6 months

Hepatitis B — Treatment, Monitoring & Adherence

Treatment Indications (EASL / AASLD Criteria)

Treatment is indicated when two or more of the following triad are met:

1. HBV DNA (Viral Load)

HBeAg+ patients: >20,000 IU/mL
HBeAg− patients: >2,000 IU/mL
Cirrhosis present: treat at any detectable level

2. ALT (Liver Inflammation)

>2× upper limit of normal (ULN)
Persistent elevation over 3–6 months
Normal ALT alone may not trigger treatment

3. Liver Histology / Imaging

Significant fibrosis: Metavir F ≥ 2
Moderate-to-severe necroinflammation
Non-invasive: FIB-4 score, FibroScan (elastography)

⚠

Special populations: treat regardless of DNA/ALT — cirrhosis, pregnancy (>200k IU/mL), HCC risk, immunosuppression, HDV co-infection, extrahepatic manifestations

First-Line Antiviral Agents

Drug	Dose	Resistance	Key Notes
Tenofovir Disoproxil Fumarate (TDF)	300mg OD	Very low	Renal monitoring; preferred in pregnancy
Tenofovir Alafenamide (TAF)	25mg OD	Very low	Less renal/bone toxicity vs TDF; preferred if renal impairment
Entecavir (ETV)	0.5mg OD (1mg if lamivudine-experienced)	Very low	Avoid if prior lamivudine resistance (rtM204)

ℹ

Avoid older agents: Lamivudine, adefovir, telbivudine — high resistance rates. Use only if no alternative.

Pegylated Interferon-alfa (PEG-IFN)

48-week finite course; higher HBeAg seroconversion rate
Preferred in: young patients, HBeAg+, genotype A/B, high ALT, low HBV DNA
Contraindicated: decompensated cirrhosis, autoimmune disease, psychiatric disorders, pregnancy
Side effects: flu-like symptoms, cytopenias, depression, thyroid dysfunction

Treatment Endpoints & Monitoring

Primary Endpoints

HBeAg seroconversion (HBeAg+ → Anti-HBe+) with undetectable HBV DNA + normal ALT = ideal endpoint for HBeAg+ patients (can consider stopping)
HBsAg loss (functional cure) — rare but optimal outcome (<1%/year with NA therapy)
HBV DNA undetectable + normal ALT — treatment success on NA

Monitoring Schedule on Treatment

Parameter	Frequency
LFTs (ALT, AST, ALP, bilirubin)	3-monthly (first year), then 6-monthly
HBV DNA (viral load)	3-monthly until undetectable, then 6-monthly
HBeAg / Anti-HBe	6-monthly (if initially HBeAg+)
HBsAg quantification	Annually (or 6-monthly on IFN)
Renal function (eGFR, phosphate) — TDF	3-monthly initially, then 6-monthly
HCC surveillance (AFP + USS)	Every 6 months

High-Risk Situations for HBV Reactivation

Rituximab-containing chemotherapy (risk up to 80% if HBsAg+, untreated)
Stem cell transplantation
Anti-TNF therapy (adalimumab, infliximab)
High-dose steroids (>20mg prednisolone for >4 weeks)
Tyrosine kinase inhibitors
CAR-T cell therapy

Screening Before Immunosuppression

ALL patients should be screened: HBsAg + Anti-HBc IgG
If anti-HBc IgG+ only (occult): check HBV DNA; consider prophylaxis based on risk

Prophylaxis Protocol

HBsAg+: Start entecavir or tenofovir 1–4 weeks before immunosuppression
Continue for: Duration of immunosuppression + 6–12 months after (18 months for anti-CD20 therapy)
Occult HBV (HBcAb+ only) high-risk therapy: Prophylaxis or close monitoring (HBV DNA every 1–3 months)

⚠

Reactivation can be fatal. Presents as acute-on-chronic liver failure. Prevention is critical — screen BEFORE starting immunosuppression, not after.

Nursing Adherence Support for Long-Term Antiviral Therapy

Barriers to Adherence (Common in GCC)

Cost of medication (insurance coverage issues for expats)
Stigma — fear of disclosure at work/family
Asymptomatic disease → perceived lack of urgency
Medication fatigue (indefinite treatment)
Ramadan fasting — altered medication timing
Travel between countries; supply chain issues
Language barriers in multicultural GCC workforce

Nursing Strategies

Educate: "Undetectable = protected liver" — reinforce why DNA suppression matters
Pill reminders: alarm apps, blister packs, daily pill box
Ramadan counselling: oral medications can be taken at iftar/suhoor — discuss with physician for exact timing of once-daily drugs
Stigma support: HIV/hepatitis stigma-free counselling; patient support groups
Motivational interviewing techniques
Written education materials in patient's native language (Arabic, Tagalog, Hindi, Urdu)
HCC surveillance reminders — link to appointment booking

Never abruptly stop NA therapy without physician guidance — rebound hepatitis flare can cause liver failure.

Hepatitis C — Diagnosis, Genotypes & DAA Treatment

Transmission & Epidemiology

Main Transmission Routes

IVDU (injecting drug use): Most common in developed countries; sharing needles/paraphernalia
Nosocomial: Unsafe injections, contaminated medical equipment, blood transfusion (pre-1992 blood screening era)
Vertical (mother-to-child): ~5%; higher if HIV co-infected
Sexual: Low risk heterosexual; higher risk MSM (especially HIV+)
Tattoos/piercings: Unsterilised equipment
Needle-stick: HCW occupational exposure (risk ~1.8%)

⚠

GCC Context: Egyptian expatriates historically carry the world's highest HCV prevalence (genotype 4 dominant) due to prior iatrogenic transmission from schistosomiasis treatment campaigns.

HCV Characteristics

No vaccine available
No natural protective immunity after clearance
~15–25% spontaneous clearance in acute phase
75–85% progress to chronic infection

HCV Testing Strategy

Screening Algorithm

Anti-HCV antibody — initial screening test. Window period: ~8–11 weeks. ELISA 3rd/4th generation.

If Anti-HCV +ve: Confirm with HCV RNA (PCR) — detectable within 1–2 weeks of exposure

If HCV RNA +ve: Active (chronic or acute) infection — refer for treatment

If Anti-HCV +ve, RNA −ve: Resolved infection (past) or false positive Ab — repeat RNA in 12 weeks

If recent exposure suspected and Ab −ve: Test HCV RNA directly (window period)

Additional Tests

HCV genotype: Guides treatment choice (though pangenotypic DAAs available)
Liver fibrosis: FIB-4 score, FibroScan, or liver biopsy (cirrhosis impacts treatment duration)

HCV Genotypes 1–6

Genotype	Global Distribution	GCC / Middle East Relevance	Treatment Response
GT1a & 1b	Western Europe, N. America, Russia	Present in GCC expat communities	Sofosbuvir/ledipasvir or glecaprevir/pibrentasvir 8–12 wks
GT2	W. Africa, Japan	Low prevalence in GCC	Sofosbuvir + ribavirin historically; now pangenotypic preferred
GT3	S. Asia (India, Pakistan, Bangladesh)	Common in South Asian expats (GCC)	Harder to treat; sofosbuvir/velpatasvir ± ribavirin
GT4	Egypt, Middle East, sub-Saharan Africa	Most common in Egyptian community; dominant in GCC region	Glecaprevir/pibrentasvir or sofosbuvir-based; excellent SVR
GT5 & 6	S. Africa; SE Asia	Rare in GCC	Pangenotypic DAAs effective

What is SVR12?

Sustained Virological Response at 12 weeks post-treatment = undetectable HCV RNA 12 weeks after completing treatment. SVR12 = cure. Probability of relapse after SVR12 is <1%.

Regimen	Genotypes	Duration	SVR12	Key Points
Sofosbuvir / Ledipasvir (Harvoni)	GT1, 4, 5, 6	8–12 wks	>95%	Can be 8 wks if treatment-naive, no cirrhosis, low viral load
Glecaprevir / Pibrentasvir (Maviret) — pangenotypic	All GT1–6	8 wks (no cirrhosis) / 12 wks (compensated cirrhosis)	>97%	Drug-drug interactions: statins, cyclosporin; avoid in decompensated cirrhosis
Sofosbuvir / Velpatasvir (Epclusa) — pangenotypic	All GT1–6	12 wks	>95%	± Ribavirin for decompensated cirrhosis
Sofosbuvir / Velpatasvir / Voxilaprevir (Vosevi)	All GT (salvage)	12 wks	>96%	For prior DAA failure; NS5A + NS3/4A + NS5B triple class

Monitoring During DAA Therapy (Minimal)

HCV RNA at treatment week 4 (optional, confirms on-treatment response)
HCV RNA at end of treatment (EOT)
HCV RNA at 12 weeks post-treatment (SVR12) = cure assessment
LFTs at baseline and SVR12
Drug-drug interaction (DDI) check at baseline — especially PPIs, HIV ARVs, immunosuppressants, statins

✓

Post-SVR: After cure, HCV Ab remains positive lifelong (past infection marker). HCV RNA becomes negative. Re-infection is possible — continue harm reduction strategies in PWID.

Chronic HCV Complications

Hepatic

Cirrhosis (~20–30% over 20 years)
Hepatocellular carcinoma (HCC)
Portal hypertension
Decompensated liver disease

Extrahepatic (Immune-mediated)

Cryoglobulinaemia — vasculitis, purpura, arthralgia, neuropathy (type II & III)
Membranoproliferative glomerulonephritis
Lymphoma (NHL)
Thyroid dysfunction (Hashimoto's)

Metabolic

Hepatic steatosis (especially GT3)
Insulin resistance / type 2 DM
Fatigue, cognitive impairment ("brain fog")
Depression, reduced quality of life

Harm Reduction & PWID (People Who Inject Drugs)

Needle/Syringe Exchange Programs

Provision of sterile needles and syringes
Safe disposal of used sharps (sharps bins)
Naloxone provision for overdose prevention
Linkage to drug treatment services
HCV testing at point of care

Nursing Role in Harm Reduction

Non-judgmental, trauma-informed care
Educate on HCV transmission and re-infection risk
Encourage opiate substitution therapy (methadone/buprenorphine) — improves treatment outcomes
DAA therapy is as effective in PWID as general population (with support)
Address housing and social determinants of health
Peer support programs

ℹ

WHO 2030 targets: 90% diagnosis, 80% treatment, 65% reduction in mortality. Treating PWID is essential for elimination — they are the main reservoir in high-income countries.

Complications, Surveillance & Advanced Liver Disease

Cirrhosis Complications — Overview

Portal Hypertension

HVPG >10 mmHg = clinically significant
Splenomegaly + thrombocytopaenia
Portosystemic shunts (caput medusae, haemorrhoids)
Varices formation

Oesophageal Varices

Screen with OGD at cirrhosis diagnosis
Repeat: every 2 yrs (no varices), annually (small varices)
Primary prophylaxis: non-selective β-blocker (propranolol/carvedilol) or EVL if large varices
Variceal bleed: resuscitate, Terlipressin + Abx + EVL

Ascites

Most common complication of cirrhosis
1st line: low-sodium diet + spironolactone ± furosemide
Refractory: large volume paracentesis + albumin (8g/L drained)
TIPS (transjugular intrahepatic portosystemic shunt) for refractory cases

SBP (Spontaneous Bacterial Peritonitis)

PMN >250 cells/mm³ on ascitic tap = diagnostic
Treatment: IV cefotaxime 2g TDS × 5 days
Albumin 1.5g/kg day 1 + 1g/kg day 3 (prevents HRS)
Long-term prophylaxis: norfloxacin / ciprofloxacin

Hepatic Encephalopathy (HE)

Identify/treat precipitant: infection, GI bleed, constipation, drugs, electrolytes
Lactulose: 15–30mL TDS titrated to 2–3 soft stools/day
Rifaximin 550mg BD (secondary prevention)
Protein restriction NOT recommended
Nutritional support: BCAA-enriched if needed

Hepatorenal Syndrome (HRS)

Type 1 (AKI): rapidly progressive, poor prognosis
Type 2 (CKD): gradual, associated with refractory ascites
Terlipressin + albumin = mainstay treatment
Avoid nephrotoxins: NSAIDs, aminoglycosides, contrast
Liver transplant = definitive treatment

Who Requires HCC Surveillance?

All patients with cirrhosis (any aetiology)
HBV patients: even without cirrhosis if — male >40 yrs, female >50 yrs, family history HCC, Asian/African origin, active HBV replication
HCV patients with advanced fibrosis (F3–F4)
Continue surveillance even after SVR12 (HCV cure) if cirrhosis present

Surveillance Protocol

Ultrasound abdomen (USS) every 6 months
AFP (alpha-fetoprotein) every 6 months (as adjunct)
AFP alone insufficient for surveillance
If USS inconclusive: contrast-enhanced CT or MRI (LI-RADS scoring)

HCC Diagnosis (EASL Criteria)

Nodule <1 cm: repeat USS in 3–4 months
Nodule >1 cm in cirrhotic liver: characteristic arterial enhancement + washout on CT/MRI = diagnostic (no biopsy needed)
LI-RADS 5 = definitely HCC

Barcelona Clinic Liver Cancer (BCLC) Staging

0/A (Very early/Early): Resection or ablation (curative)
B (Intermediate): Transarterial chemoembolisation (TACE)
C (Advanced): Sorafenib / lenvatinib / immunotherapy (atezolizumab + bevacizumab)
D (Terminal): Best supportive care
Transplant criteria: Milan criteria (1 nodule ≤5cm or 3 nodules ≤3cm each)

MELD Score & Transplant Listing

Model for End-Stage Liver Disease — predicts 3-month mortality in cirrhosis.

MELD = 3.78×ln[bilirubin] + 11.2×ln[INR] + 9.57×ln[creatinine] + 6.43

MELD Score	3-Month Mortality	Action
<10	<2%	Monitor outpatient
10–19	6%	Close follow-up, consider listing
20–29	20%	List for transplant
30–39	53%	Urgent listing
≥40	71%	Very urgent — ICU consideration

Post-Liver Transplant Prophylaxis

HBV: HBIG + tenofovir or entecavir indefinitely (prevents recurrence)
HCV: DAA therapy pre- or post-transplant; SVR12 prevents recurrence; excellent outcomes
Annual HCC surveillance continues post-transplant

HDV (Hepatitis D) — Co-infection & Superinfection

⚠

HDV requires HBV to replicate — it is a defective satellite virus. Only HBsAg+ patients are at risk.

Two Patterns

Co-infection (HBV + HDV simultaneously): Acute, usually self-limiting, 5% chronic risk. Presents as acute hepatitis, may have biphasic ALT peak.
Superinfection (HDV in chronic HBV carrier): 70–90% progress to chronic HDV. Worst prognosis — accelerated cirrhosis (5–10 years), highest HCC risk.

Diagnosis

Anti-HDV antibody (IgM = acute, IgG = chronic)
HDV RNA (PCR) — confirms active replication

Treatment

PEG-IFN-alfa: only established therapy (48–72 weeks)
Bulevirtide (entry inhibitor) — newly approved in Europe; blocks HDV entry into hepatocytes
NAs (TDF/ETV) suppress HBV but NOT HDV replication
Prevention: HBV vaccination = HDV prevention (HDV cannot exist without HBV)

GCC Context & Examination Preparation

GCC-Specific Epidemiology & Clinical Context

HBV in the GCC

Intermediate-high prevalence in South Asian expats (Bangladesh, India, Pakistan): HBsAg prevalence ~2–5%
Filipino expat community: significant HBV burden
Mandatory pre-employment screening for HBsAg in all 6 GCC countries — non-immune workers vaccinated
Labour camp settings: crowding → outbreak risk
Vertical transmission: key driver in endemic origin countries — birth-dose vaccine campaigns critical
National HBV vaccination programs: universal infant vaccination in UAE, KSA, Qatar since 1990s

HCV in the GCC

Egyptian expat community: Highest HCV prevalence globally historically (~10–20% in older cohorts), predominantly genotype 4
Linked to mass schistosomiasis treatment with IV tartar emetic (pre-1980s) using shared needles
DAA treatment highly effective; GCC countries increasingly providing universal access
WHO hepatitis elimination programmes active in Egypt — significant progress

HEV in the GCC

Sporadic cases, particularly in travellers and expats from India/Pakistan (genotype 1 endemic)
Waterborne outbreaks reported in labour accommodations with poor sanitation
Pregnant workers particularly at risk — must be identified early
Food safety inspections and water quality monitoring = key public health tools

Blood Safety in GCC

All GCC blood banks screen donors for HBsAg, anti-HCV, HCV NAT, HIV, syphilis, HTLV
HBV NAT testing implemented in most GCC countries
Haemovigilance systems in place; transfusion-transmitted hepatitis now rare
Nucleic Acid Testing (NAT) shortens window period vs antibody tests

Ramadan & Medication Adherence

Once-daily DAAs (sofosbuvir-based, glecaprevir/pibrentasvir) can be taken at iftar (sunset) or suhoor (pre-dawn)
Nucleoside analogues (entecavir, tenofovir) — once daily, flexible timing, take with water
Avoid dehydration — important for renal monitoring in TDF patients
Counsel patients before Ramadan starts; never self-discontinue antiviral therapy

Immediate First Aid (First 2 Minutes)

Wash wound with soap and water for 2–3 minutes
Allow wound to bleed freely (do NOT suck)
Apply antiseptic (betadine/alcohol)
For mucous membrane splash: flush with copious water for 5 minutes
Remove contact lenses if eye exposure; irrigate both eyes

Reporting (Within 1–2 Hours)

Report to supervisor and infection control / occupational health immediately
Document: date/time, type of device, body fluid, depth of injury, source patient ID
Most GCC hospitals have 24/7 on-call occupational health service

Post-Exposure Actions by Pathogen

Pathogen	PEP Available?	Timeline	Action
HBV	Yes	Within 24–48 hrs	HBIG + HBV vaccine (if unvaccinated/non-immune)
HCV	No PEP	Monitor	Baseline HCV Ab + RNA; repeat at 4–6 wks, 3 months, 6 months; early treatment if seroconverts
HIV	Yes	Within 2 hrs (max 72 hrs)	HIV PEP 28-day course (consult ID); follow-up HIV test at 6 wks, 3 months

⚠

DHA/DOH licensing requirements: All HCWs must demonstrate HBV immunity (anti-HBs ≥10 mIU/mL) or documented vaccination. Non-responders must follow strict injury protocols.

DHA / DOH / SCFHS Examination Preparation

High-Yield Serology Questions

MNEMONIC: HBsAg is the Culprit Marker

HBsAg + = actively infected (acute OR chronic)
Anti-HBs + alone = vaccinated (no core Ab = never naturally infected)
Anti-HBs + Anti-HBc IgG + = past infection, resolved
Anti-HBc IgM + = acute infection (even if HBsAg going negative in window)
HBsAg + HBeAg + = highly infectious, high replication

Classic Exam Vignettes

Pregnant woman at 28 weeks: HBsAg+, HBV DNA 500,000 IU/mL → Start tenofovir NOW + plan HBIG + vaccine for baby at birth
Healthcare worker after needlestick: unvaccinated, source HBsAg+ → HBIG within 24hrs + start HBV vaccine series
Asymptomatic man: HBsAg+, normal ALT, HBV DNA 800 IU/mL → Inactive carrier — monitor, no treatment yet
Patient starting rituximab: anti-HBc IgG+, HBsAg− → Check HBV DNA; give antiviral prophylaxis before immunosuppression
Egyptian man with elevated ALT: HCV Ab+, HCV RNA+ → Genotype 4, start glecaprevir/pibrentasvir 8 weeks, expect SVR12 >97%

HBV Vaccination — Exam Facts

Schedule: 0, 1, 6 months
Check anti-HBs 4–8 weeks after 3rd dose
Protective level: ≥10 mIU/mL
Non-responder after 6 doses: check HBsAg (may be chronic); advise standard precautions
Birth dose: within 12 hours of birth (for babies of HBsAg+ mothers)
HBIG dose for neonate: 0.5 mL IM (different limb to vaccine)

DAA Regimen — Exam Facts

SVR12 = cure for HCV
Glecaprevir/pibrentasvir = pangenotypic, 8 weeks for treatment-naive without cirrhosis
Sofosbuvir/ledipasvir = GT1 and GT4, check drug interactions (PPIs reduce absorption)
After SVR12: HCV Ab remains +, RNA becomes −
Re-infection is possible — continue harm reduction

Fulminant Hepatic Failure Triggers (Exam)

HAV in patients with pre-existing chronic liver disease
HEV in pregnancy (3rd trimester)
Drug-induced: paracetamol overdose, INH, halothane
Wilson's disease, acute Budd-Chiari, autoimmune hepatitis

Numbers to Memorise

Parameter	Value
HAV incubation	15–50 days
HBV incubation	45–180 days
HCV incubation	14–180 days
HEV mortality in pregnancy	15–25%
Chronic HBV risk (perinatal)	90%
Chronic HCV risk (adult)	75–85%
Anti-HBs protective level	≥10 mIU/mL
Treat HBV (HBeAg+) DNA threshold	>20,000 IU/mL
MELD score for urgent transplant	≥30
HCC surveillance interval	6 months (USS + AFP)

Quick Summary Comparison Table — All Hepatitis Viruses

Feature	HAV	HBV	HCV	HDV	HEV
Transmission	Faecal-oral	Parenteral, sexual, vertical	Parenteral (IVDU, nosocomial)	Parenteral (requires HBV)	Faecal-oral, waterborne, zoonotic
Chronicity	No	Yes (5–90%)	Yes (75–85%)	Yes (superinfection)	No (except immunocomp)
Vaccine	Yes	Yes	No	Via HBV vaccine	China only
Treatment	Supportive	TDF / ETV / PEG-IFN	DAAs (SVR12 = cure)	PEG-IFN / Bulevirtide	Supportive
HCC risk	No	Yes (direct)	Via cirrhosis	High (co-infection)	No
Pregnancy danger	Low	Vertical transmission	Vertical 5%	Worsened if HBV	Very high (15–25% FHF)
Key GCC concern	Outbreaks (food/water)	South Asian/Filipino expats; pre-employment screen	Egyptian expats; GT4	HBV co-infection	Labour camp waterborne outbreaks; pregnant workers

🧬 Viral Hepatitis — Comprehensive GCC Nursing Guide

Hepatitis A & E — Enterically Transmitted Hepatitis

Hepatitis A (HAV)

Key Facts

Clinical Features

Diagnosis

Hepatitis E (HEV)

Key Facts

Diagnosis

HAV Vaccination & Post-Exposure Prophylaxis

Vaccination Schedule

Indications for Vaccination

Post-Exposure Prophylaxis (within 2 weeks)

Acute Hepatitis Management

Supportive Care

Nursing Monitoring

⚠ Fulminant Hepatic Failure (FHF) — Warning Signs

Clinical Red Flags

Hepatic Encephalopathy Grades

Immediate Actions

Infection Control Measures

Standard Precautions (all hepatitis)

Contact Precautions (HAV/HEV specific)

Hepatitis B — Serology, Natural History & Prevention

🧪 Interactive HBV Serology Interpreter

Phases of Chronic HBV Infection

Natural History & Complications

HBV Vaccination Program

Standard Schedule (3-dose)

Accelerated (rapid immunity needed)

Response Assessment

GCC Requirement

Vertical Transmission Prevention & Healthcare Worker Exposure

Perinatal Transmission Prevention

Healthcare Worker Needlestick / Exposure Protocol

Hepatitis B — Treatment, Monitoring & Adherence

Treatment Indications (EASL / AASLD Criteria)

1. HBV DNA (Viral Load)

2. ALT (Liver Inflammation)

3. Liver Histology / Imaging

First-Line Antiviral Agents

Pegylated Interferon-alfa (PEG-IFN)

Treatment Endpoints & Monitoring

Primary Endpoints

Monitoring Schedule on Treatment

High-Risk Situations for HBV Reactivation

Screening Before Immunosuppression

Prophylaxis Protocol

Nursing Adherence Support for Long-Term Antiviral Therapy

Barriers to Adherence (Common in GCC)

Nursing Strategies

Hepatitis C — Diagnosis, Genotypes & DAA Treatment

Transmission & Epidemiology

Main Transmission Routes

HCV Characteristics

HCV Testing Strategy

Screening Algorithm

Additional Tests

HCV Genotypes 1–6

What is SVR12?

Monitoring During DAA Therapy (Minimal)

Chronic HCV Complications

Hepatic

Extrahepatic (Immune-mediated)

Metabolic

Harm Reduction & PWID (People Who Inject Drugs)

Needle/Syringe Exchange Programs

Nursing Role in Harm Reduction

Complications, Surveillance & Advanced Liver Disease

Cirrhosis Complications — Overview

Portal Hypertension

Oesophageal Varices

Ascites

SBP (Spontaneous Bacterial Peritonitis)

Hepatic Encephalopathy (HE)

Hepatorenal Syndrome (HRS)

Who Requires HCC Surveillance?

Surveillance Protocol

HCC Diagnosis (EASL Criteria)

Barcelona Clinic Liver Cancer (BCLC) Staging